$60.81▴ 0.12%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Vaxcyte, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days3 articles
2 bullish1 neutral0 bearish
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm- Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials